Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab Meeting Abstract
| Authors: | Kyi, C.; Van Dongen, M.; Rottey, S.; Bermejo, I. M.; Mittag, D.; Gouveia, D.; Bol, K.; Yan, C.; Joe, A. K.; Laus, G.; Moreno, V. |
| Abstract Title: | Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400465 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.2520 |
| Notes: | Meeting Abstract: 2520 -- Source: Wos |
